• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1243312 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
  o" x3 E# A3 U- I% O: xNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
8 G$ W; K3 F& P& s+ Author Affiliations# ^) P- U/ Y8 i4 p
+ s9 \7 [# P/ X0 ?
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
7 U9 Y. a" x1 U$ y% q9 m- Y2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
" \* A0 r; F1 E3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 7 U  c, [2 V9 i- m: Q0 r9 ^5 L
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan ; n; B) }7 H1 |
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
' L7 _7 m, D$ g. H6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
1 h1 I- n6 ~( p- A7Kinki University School of Medicine, Osaka 589-8511, Japan 2 r5 \" ~8 E& I) }- b" H) G
8Izumi Municipal Hospital, Osaka 594-0071, Japan
) x1 i, T% {3 k* _) `3 ]+ m! P9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
0 O( H% H$ Y( C9 u8 D% L2 q% ?Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp $ I, Y- ^; q5 ~* F' \
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. ( Y. x# S8 b9 \2 e6 S! U
/ `& C3 U! R' g# |4 `
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type . A: k9 Z7 N: d( e! v+ C

! ~! t8 \3 u& R6 p7 A- T5 \Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
. p  P- r9 Z- C7 x/ m4 ?. }" Y4 w3 e% p% l0 `* X. C6 [
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
4 j6 J  @+ ]$ b/ E
) B  E( F2 |, H- V) `( g" PPublished online on: Thursday, December 1, 2011
3 D7 v/ B! ~8 T# V
/ b3 f9 ~- w" NDoi: 10.3892/ol.2011.507 0 F5 X/ l* b* F
$ F! K& Q4 J- D) N
Pages: 405-410 ! Q. b6 ~6 e) m! T9 p3 h. V! B+ ?6 R( G
" D9 M3 F/ X; x4 c! }$ \
Abstract:
3 }2 }; T+ W6 v* qS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.; g8 g9 p# F1 G. z
  {; J2 ^3 U6 N  q) ]
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population* N# c% B: l# K# e( a) i! U
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
2 ~$ D' f: n1 }9 D8 {7 L' a+ Author Affiliations* ^8 W" K% X! q/ r6 N  h9 E" o
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu ) {- B7 V# U- r( y# t; X2 e
2Department of Thoracic Surgery, Kyoto University, Kyoto ! ]# N* P1 q/ q7 [5 B8 r
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan " L4 N5 ^5 X$ p: e
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp 0 n+ g, w6 G2 R( q1 a
Received September 3, 2010.
# k1 D& I0 ~' \% l( w5 [Revision received November 11, 2010. ! H6 H& p6 c) i' F$ Q
Accepted November 17, 2010.
7 z" P+ c7 b5 a6 Q; o1 IAbstract' D! X. L2 a, |) m* Q
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. $ Q+ x# v1 k: B% Z2 {. |( [* N, [
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. ( v0 g0 \! @1 X
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
0 o  F0 \  ]. {" h; [- YConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. 0 T$ C' {* b+ V) M
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
. f! i* Y/ _4 A: t今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?: F) a3 A) N+ p) w5 S
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy' `1 s8 K& g1 p5 F+ N+ C
http://clinicaltrials.gov/ct2/show/NCT01523587. ]3 x9 m4 }8 M9 }4 s

& l2 L  k6 `8 e, P2 {BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
0 u4 S5 \- [2 J$ n' ^# ~& Y# F, xhttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 + ]! e4 T' J  l% \9 G
/ o- O% B: E0 k5 @7 z8 e4 E
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。* l6 Z2 V6 f' Y' b/ T* [, q+ U
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 : X7 C8 K5 J* z
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。& V4 |' G% Z5 Q# I# I& f; q: y
至今为止,未出 ...
- ~$ o" M- V# q# z
没有副作用是第一追求,效果显著是第二追求。
% A0 {1 C: r- z& O& {6 q7 z* X不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表